Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louis M Staudt

Showing results (111-120 of 286) with videos related to

Pageof 29
Sort By:
Cell Reports|March 10, 2021
Most non-canonical proteins uniquely populate the proteome or immunopeptidomeMaria Virginia Ruiz Cuevas, Marie-Pierre Hardy, Jaroslav Hollý, et al.
Journal of Cell Science|August 6, 2009
Engagement of CD81 induces ezrin tyrosine phosphorylation and its cellular redistribution with filamentous actinGreg P Coffey, Ranjani Rajapaksa, Raymond Liu, et al.
BMC Immunology|September 17, 2004
Distinct gene expression profiles in different B-cell compartments in human peripheral lymphoid organsYulei Shen, Javeed Iqbal, Li Xiao, et al.
The New England Journal of Medicine|April 12, 2013
Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphomaKieron Dunleavy, Stefania Pittaluga, Lauren S Maeda, et al.
Leukemia & Lymphoma|April 15, 2021
Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphomaWyndham H Wilson, Tycel Phillips, Leslie Popplewell, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 20, 2016
Regulation of normal B-cell differentiation and malignant B-cell survival by OCT2Daniel J Hodson, Arthur L Shaffer, Wenming Xiao, et al.
Leukemia & Lymphoma|October 10, 2009
Decreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IVSarah T Wilkinson, Diane R Fernandez, Shawn P Murphy, et al.
Blood|June 2, 2019
A novel model of controlling PD-L1 expression in ALK<sup>+</sup> anaplastic large cell lymphoma revealed by CRISPR screeningJing-Ping Zhang, Zhihui Song, Hong-Bo Wang, et al.
Nature|June 24, 2008
IRF4 addiction in multiple myelomaArthur L Shaffer, N C Tolga Emre, Laurence Lamy, et al.
British Journal of Haematology|May 4, 2021
Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinibSriram Balasubramanian, Songbai Wang, Christopher Major, et al.
Pageof 29

Showing results (111-120 of 286) with videos related to

Sort By:
Pageof 29
Cell Reports|March 10, 2021
Most non-canonical proteins uniquely populate the proteome or immunopeptidomeMaria Virginia Ruiz Cuevas, Marie-Pierre Hardy, Jaroslav Hollý, et al.
Journal of Cell Science|August 6, 2009
Engagement of CD81 induces ezrin tyrosine phosphorylation and its cellular redistribution with filamentous actinGreg P Coffey, Ranjani Rajapaksa, Raymond Liu, et al.
BMC Immunology|September 17, 2004
Distinct gene expression profiles in different B-cell compartments in human peripheral lymphoid organsYulei Shen, Javeed Iqbal, Li Xiao, et al.
The New England Journal of Medicine|April 12, 2013
Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphomaKieron Dunleavy, Stefania Pittaluga, Lauren S Maeda, et al.
Leukemia & Lymphoma|April 15, 2021
Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphomaWyndham H Wilson, Tycel Phillips, Leslie Popplewell, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 20, 2016
Regulation of normal B-cell differentiation and malignant B-cell survival by OCT2Daniel J Hodson, Arthur L Shaffer, Wenming Xiao, et al.
Leukemia & Lymphoma|October 10, 2009
Decreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IVSarah T Wilkinson, Diane R Fernandez, Shawn P Murphy, et al.
Blood|June 2, 2019
A novel model of controlling PD-L1 expression in ALK<sup>+</sup> anaplastic large cell lymphoma revealed by CRISPR screeningJing-Ping Zhang, Zhihui Song, Hong-Bo Wang, et al.
Nature|June 24, 2008
IRF4 addiction in multiple myelomaArthur L Shaffer, N C Tolga Emre, Laurence Lamy, et al.
British Journal of Haematology|May 4, 2021
Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinibSriram Balasubramanian, Songbai Wang, Christopher Major, et al.
Pageof 29